Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sunhawk Vision Biotech Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is being conducted by 1 distinct examiner in 1 distinct art unit. Such a focused profile suggests that the company's current efforts are concentrated on a specific application or set of claims within the Biotechnology & Pharmaceuticals field.
The busiest examiner for this company is ZAHORIK, AMANDA MARY, who is responsible for the 1 pending office action. Since there is only 1 distinct examiner involved, the success of the current prosecution depends on addressing the specific concerns raised by ZAHORIK, AMANDA MARY. The presence of only 1 distinct art unit means the company is not currently navigating the differing procedural expectations of multiple units.
With 1 pending office action and 1 distinct examiner, the administrative complexity for Sunhawk Vision Biotech Inc. is low. ZAHORIK, AMANDA MARY, as the busiest examiner with 1 pending action, represents the entirety of the company's current pending workload. This focus within 1 distinct art unit allows for a targeted approach to resolving the 1 pending office action currently on file.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZAHORIK, AMANDA MARY | 1 | 58.3% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260773 | METHOD FOR TREATING OCULAR SURFACE DISEASES | ZAHORIK, AMANDA MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260773 | METHOD FOR TREATING OCULAR SURFACE DISEASES | ZAHORIK, AMANDA MARY | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260773 | METHOD FOR TREATING OCULAR SURFACE DISEASES | ZAHORIK, AMANDA MARY | 1636 | §103§112 | Non-Final OA | — | Pending | Jul 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSunhawk Vision Biotech Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amanda Mary Zahorik has the most, with 1 of Sunhawk Vision Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.